RxDoctor Payments Data

Mark Rodgers, MD

Internal Medicine · Arlington, TXNPI 1811954936

Payments from drug & device makers

$8,405in general payments, 2019–2025

Across 504 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$1K
  • Novo Nordisk$630
  • AstraZeneca$612
  • GSK$514
  • Boehringer Ingelheim$357
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$1,20014%
  • Food & beverage$7,18786%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,405 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$38,736
Medicare patients
179
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$225,113
JardianceEmpagliflozin54$69,532
EliquisApixaban78$65,212
MounjaroTirzepatide26$33,673
Nurtec OdtRimegepant Sulfate17$22,499
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$21,635
TrulicityDulaglutide21$20,606
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$18,614
LinzessLinaclotide27$18,162
XareltoRivaroxaban11$15,305
MyrbetriqMirabegron14$10,396
Celecoxib202$7,109
SymbicortBudesonide/Formoterol Fumarate26$6,185
SynthroidLevothyroxine Sodium74$5,432
Lidocaine34$5,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$630$225,113166 claims
PfizerEliquis, Nurtec Odt, Paxlovid$266$90,552124 claims
Boehringer IngelheimJardiance$357$69,53254 claims
Lilly USA, LLCMounjaro, Trulicity$293$54,28047 claims
AbbVieLinzess, Synthroid, Armour Thyroid$1,041$25,289121 claims
GSKTrelegy Ellipta$514$21,63529 claims
Johnson & JohnsonXarelto$140$15,30511 claims
Astellas Pharma US IncMyrbetriq$94$10,39614 claims
AstraZenecaSymbicort$612$6,18526 claims
MerckDulera$164$3,91711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →